Baroreflex activation therapy for heart failure with reduced ejection fraction: A comprehensive systematic review and meta-analysis

• DOI: 10.1016/j.heliyon.2024.e24177
• Publication Date: 2024-01-09T16:58:02Z
• Authors: Ruijie Shi; Tong Sun; Mengxi Wang; Qian Xiang; Yuhan Ding; Siyuan Yin; Yan Chen; Le Shen; Peng Yu; Xiaohu Chen
• Keywords: Social sciences (General); H1-99; Reduced ejection fraction; Meta-analysis; Q1-390; Science (General); 0302 clinical medicine; Randomized controlled trials; Heart failure; Baroreflex activation therapy; Systematic Review and Meta-Analysis

BackgroundIn recent years, baroreflex activation therapy (BAT) has been utilized to treat heart failure with reduced ejection fraction (HFrEF). However, the supporting literature on its efficacy and safety is still limited. This investigation elucidates effects of BAT in HFrEF patients provide a reference for future clinical applications.MethodsThis follows Preferred Reporting Items Systematic Reviews Meta-Analysis (PRISMA) 2020 guidelines. Relevant investigations use were searched selected from 5 databases, including Web Science, MEDLINE, PubMed, Embase, Cochrane Library, inception December 2022. The methodological quality eligible articles was assessed via risk bias tool, meta-analysis, RevMan (5.3) used.ResultsRandomized controlled trials comprising 343 participants which revealed that patients, enhanced levels LVEF (MD: 2.97, 95 % CI: 0.53 5.41), MLHFQ −14.81, −19.57 −10.06) 6MWT 68.18, 51.62 84.74), whereas LVEDV −15.79, −32.96 1.37) DBP −2.43, −4.18 −0.68).ConclusionIt concluded an efficient treatment option patients. validate this investigation, further randomized multiple centers large sample sizes are needed.